New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NSRGY;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 >>
February 1, 2016
10:49 EDTPFEPfizer technical comments before earnings
On the downside, an important support level to watch is at the $28 area. This level has been an important support since early 2013. If the news is a negative surprise, the $28 zone is likely to be tested from current levels. A breakdown below $28 would resolve the range bearishly. Next downside objectives may be at the following support levels: $27.30, $26.42. If the news is a bullish surprise, resistance levels to watch as potential upside objectives would be at $30.95, $31.78, and $32.91. A move above $32.50 would end the current longer-term downtrend.
08:09 EDTPFEOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
06:58 EDTPFEPortola Pharma licensed right to andexanet alfa to Bristol-Myers and Pfizer
Subscribe for More Information
06:57 EDTPFEBristol-Myers and Pfizer sign collaboration with Portola Pharmaceuticals
Subscribe for More Information
January 29, 2016
14:44 EDTPFEPfizer volatility elevated into Q4 and outlook
Subscribe for More Information
05:39 EDTPFEPfizer: LIS awards infliximab biosimilar tender to Inflectra, Reuters reports
Pfizer says that the Norwegian Drug Procurement Cooperation has awarded its product Inflectra an infliximab biosimilar tender, Reuters reports. Reference Link
<< 1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use